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Abstract
Background: Bordetella pertussis is a causative agent of pertussis or whooping cough in humans.
Pertactin (Prn), fimbriae 2 (Fim2) and fimbriae 3 (Fim3) of B. pertussis are important virulence
factors and immunogens which have been included in some acellular pertussis vaccines. In this
present study, we cloned, expressed and purified Prn, Fim2 and Fim3, respectively. The
immunogenicity and protective efficacy of the three recombinant proteins (rPrn, rFim2 and rFim3)
were investigated in mouse model.
Results: Three recombinant proteins with amount of 12 to 25 mg/L were produced. Compared
to the control mice only immunized with adjuvant, serum IgG antibody responses were significantly
induced in the mice immunized with rPrn, rFim2 or rFim3 (P < 0.001 for all three proteins).
Furthermore, T cell responses characteristic of increased production of IL-2 and TNF-α (only for
rPrn) were elicited in the mice immunized with the three proteins (P < 0.05 for all three proteins).
Immunization with rPrn, but not with rFim2 or rFim3, significantly enhanced clearance of bacteria
in the lungs of mice after intranasal challenge with B. pertussis (P < 0.05). When tested in a lethal
intracerebral infection model, certain protection was observed in mice immunized with rPrn.
Conclusions: We have developed an efficient method to produce large amounts of rPrn, rFim2,
and rFim3 from B. pertussis. The three recombinant proteins induced both humoral and cellular
immune responses in mice. Immunization with rPrn also conferred protection against pertussis in
mouse infection models. Our results indicated that the recombinant proteins still retain their
immunological properties and highlighted the potential of the recombinant proteins for the future
development of the B. pertussis vaccines.
Background
Pertussis or whooping cough is an infectious respiratory
disease caused by the bacterium Bordetella pertussis.
Despite being preventable by vaccination, pertussis
remains one of the top ten causes of death worldwide in
childhood, mainly in unvaccinated children [1]. Accord-
ing to the World Health Organization (WHO), about 17.6
million cases of pertussis occurred all over the world and
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of deaths occurred in the developing countries.
Immunization with whole cell pertussis vaccines (WPVs)
was started in the middle of 20th Century and has signifi-
cantly reduced the incidence of pertussis in many coun-
tries including China [3]. However, these WPVs have
drawbacks in causing side effects such as local pain, red-
ness, swelling, fever, and fussiness [4,5]. Due to the fear of
side effects and the need for booster immunizations in
older age groups, acellular pertussis vaccines (APVs) were
developed and they were first introduced in Japan in 1981
[6]. Typically current APVs are comprised of antigens
directly purified from cultured B. pertussis bacteria. They
may include pertussis toxin (PT), filamentous hemagglu-
tin (FHA), Prn, or Fim2 and Fim3. Clinical efficacy trials
carried out in Sweden and Italy indicated that APVs con-
taining two or three more components (such as Prn, Fim2
and Fim3) were more effective than the PT alone and/or
FHA based vaccines [7,8]. In China, two component APVs
containing PT and FHA have been developed and utilized
since 1990s [9].
Prn, originally called 69-kDa outer membrane protein,
has been shown to play a role in invasion of eukaryotic
cells by B. pertussis bacteria [10]. It has also reported that
Prn elicits both humoral and cellular immune responses
in mice and protects infant mice from respiratory chal-
lenge by B. pertussis [11]. However, the low yield of Prn
from cells or the culture supernatant of B. pertussis has
been a limiting factor in the production of Prn-containing
APVs [12]. Fimbriae (Fim), also known as pili and agglu-
tinogen, belong to bacterial adhesins which are expressed
on the B. pertussis surface. Fim2 and Fim3 are closely
related in molecular weight (22 kDa and 22.5 kDa) but
are serologically distinct [13-15]. Similar characteristics
and molecular weight of Fim2 and Fim3 hampered the
production of separate proteins from B. pertussis [14,15].
So far there have been no separate purified Fim2 and Fim3
available. In addition, antigenic divergence between vac-
cine strains and clinical isolates [16-18] as well as the pos-
sible presence of other reactogenic contaminants [19],
should be considered during purification of those pro-
teins. To overcome these difficulties, attempts have been
made to express the proteins in vitro by recombinant tech-
nology. This technology has advantages regarding of
higher yield and controlled production of recombinant
proteins at a high homogeneity [20,21]. If such a platform
could be established, not only the cost for APV production
could be reduced, but also the ability to deal with the anti-
genic shift could be enhanced.
In this report, we described a method that can be used to
produce large amount of rPrn, rFim2 and rFim3 proteins.
By using these proteins, we studied their immunogenicity
and protective properties in mouse model.
Results
Expression and characterization of rPrn, rFim2 and rFim3
To generate recombinant proteins rPrn, rFim2 and rFim3
in Escherichia coli, respective genes were amplified from a
Chinese vaccine strain CS and cloned into a protein
expression vector. Three expression plasmids were con-
structed, and the DNA sequences were confirmed by DNA
sequencing. Protein expression was induced by isopropyl-
β-D-thiogalactopyranoside (IPTG), and purification of
the three recombinant proteins was achieved through
nickel affinity chromatography with the HisTrapTM HP
column. Each purified protein migrated as a single band
with the predicted size in SDS-PAGE, of which purity was
more than 95% (Figure 1). The specificity of the bands
SDS-PAGE and Western blotting analysisFigure 1
SDS-PAGE and Western blotting analysis. (A) SDS-
PAGE of the purified recombinant proteins. The proteins 
were electrophoresed on a 10% SDS-PAGE gel under reduc-
ing condition and stained by Coomassie blue. Lane 1: Molec-
ular mass marker, the molecular mass standards are 
indicated in kDa on left side; lane 2: rPrn (10 μg); lane3: 
rFim2 (10 μg); lane 4: rFim3 (10 μg). (B) Western blotting of 
the recombinant proteins. Lane 1: Pre-stained molecular 
mass marker (170 kDa, 130, 100, 70, 55, 40, 35, 25, 15, 10, 
Fermentas), the molecular mass standards are indicated in 
kDa on left side; lane 2: rFim2 was detected with mouse anti-
Fim2 monoclonal antibodies; lane 3: rFim3 was detected with 
mouse anti-Fim3 monoclonal antibodies; lane 4: Pre-stained 
molecular mass marker, the molecular mass standards are 
indicated in kDa on right side; lane 5: rPrn was detected with 
mouse anti-Prn monoclonal antibodies; lane 6: Pre-stained 
molecular mass marker, the molecular mass standards are 
indicated in kDa on right side.Page 2 of 8
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against native forms of Prn, Fim2 or Fim3, respectively, in
Western blotting (Figure 1). By using this approach, a
large amount of proteins was obtained, at approximately
12 mg/L of rPrn, 25 mg/L of rFim2, and 19 mg/L of rFim3.
Serum antibody responses to rPrn, rFim2 and rFim3
In order to examine the antibody responses to rPrn, rFim2
and rFim3, sera of immunized mice were collected two
weeks after the second immunization. Titres of serum IgG
antibodies were measured by ELISA. Significant IgG anti-
body responses were observed in the mice immunized
with both high and low doses of rPrn, rFim2 or rFim3
when compared to the control group (P < 0.001 for all
three proteins) (Figure 2). High levels of IgG antibodies
were induced in mice immunized with high doses of the
three proteins. However, the differences were not signifi-
cant when compared to those in mice immunized with
low doses (Figure 2). When the same amount of rFim2
and rFim3 was used in immunization, IgG responses
appeared to be similar between the two groups (P =
0.056).
Serum cytokine responses to the rPrn, rFim2 and rFim3
Both Th1 (IL-2 and TNF-α) and Th2 (IL-4) cytokine
responses were determined after the second immuniza-
tion with the recombinant proteins. For IL-2, significant
higher levels were induced in mice immunized with rPrn,
rFim2 or rFim3 when compared to the control mice (P <
0.05 for all three proteins). For TNF-α, significant higher
level was only observed in mice immunized with rPrn (P
= 0.037), but not in those with rFim2 or rFim3. The IL-4
induction was not found in all groups of mice (Figure 3).
Intranasal challenge with B. pertussis
Seven days after the intranasal challenge with B. pertussis,
the bacterial loads were significantly lower in the lungs of
mice immunized with high or low doses of rPrn, com-
pared to those observed in the control mice (P = 0.021
and P = 0.039). For the mice immunized with rFim2 or
rFim3, no significant difference was observed in the bac-
terial loads in the lungs compared to the control mice
(Figure 4).
Intracerebral challenge with B. pertussis
Two weeks after the intracerebral challenge with a lethal
dose of B. pertussis, none of the mice in the control group
survived (Figure 5). In contrast, a dose-dependent protec-
tion was observed in mice immunized with different
doses of the reference vaccine. For the mice immunized
with rPrn, some protection against the lethal dose of inter-
cerebral challenge was noticed when compared to the
control mice (P = 0.005). The level of this protection pro-
vided from immunization with rPrn was clearly higher
than that from the immunization with 0.02 IU of refer-
ence vaccine (P = 0.027). The result suggested that immu-
nization with rPrn alone can confer partial protection
against a lethal intracerebral B. pertussis challenge. Such
intracerebral challenge assays were also performed in the
groups immunized with different doses of rFim2 and
rFim3. However, no significant protection was observed
as none of mice were survived in the groups immunized
with 20 μg dose of rFim2 and 4 μg dose of rFim3 and a few
(less than three) survival mice in other dose groups.
Discussion
Because of its advantages in cost, yield and purity, vaccine
based on recombinant components has been considered
Antibody responses in immunized and control miceFigure 2
Antibody responses in immunized and control mice. Two weeks after the second immunization, sera were collected, 
and IgG antibody titres were determined by ELISA. Results represent the mean antibody titres for five mice per group. An 
asterisk symbol (*) indicates a statistically significant difference (P < 0.001) between immunized and control group.Page 3 of 8
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[22], in particular for the developing countries. In the
present study, we showed that the recombinant Prn, Fim2
and Fim3 proteins can be readily expressed and purified
in large quantities from E. coli, and each recombinant pro-
tein solution is stable for up to twelve months when
stored at below -20°C. They were prepared in a large
quantity and freeze-dried. It was confirmed that the activ-
ity of freeze-dried preparation had no difference signifi-
cantly compared with liquid preparation by ELISA
method and in some animal experiments (data not
shown). The three recombinant proteins can elicit both
humoral and cellular immune responses when they were
investigated in mice. Furthermore, this recombinant tech-
nology makes it possible to avoid contaminations from
the B. pertussis components that may cause side effects in
vaccine preparations [19]. Availability of the purified
Fim2 and Fim3 also provided an opportunity to assess
their individual roles in the immunogenicity and protec-
tive efficacy.
As a virulence factor of B. pertussis, the ability of Prn to
function as adhesin has been investigated both in vitro and
in vivo [10,23]. It is reported that the Prn-mediated protec-
tion may be afforded by blocking Prn-mediated attach-
ment of B. pertussis to the host cells [24,25]. Studies on the
immunized children have also suggested that high level of
circulating antibodies against Prn are associated with pro-
tection [26,27]. Furthermore, evidence suggests that anti-
Prn antibodies may promote extracellular killing with
complement or as opsonins, and mediate killing bacteria
by phagocytes [25]. However, although antibodies spe-
cific to B. pertussis antigens confer protection, many stud-
ies have indicated that humoral immunity alone is not
sufficient to provide long-term protection against B. per-
tussis infection and that the protection against B. pertussis
requires both T cell- and B cell-mediated immunity
[28,29]. Our results showed that the antibody response
increased significantly in mice immunized with rPrn.
Immunization of rPrn also induced a Th1 response that is
characterized by the enhanced production of IL-2- and
Cytokine responses in immunized and control miceFigure 3
Cytokine responses in immunized and control mice. 
Two weeks after the second immunization, blood samples 
were collected from five mice from each group. The 
cytokines were determined by ELISA and are expressed as 
pg/mL sera. Results are the mean responses for five mice per 
group. An asterisk symbol (*) indicates a statistically signifi-
cant difference (P < 0.05) between immunized and control 
group.
Protection against intranasal challenge with B. pertussisFigure 4
Protection against intranasal challenge with B. per-
tussis. Two weeks after the second immunization, the mice 
were challenged intranasally with B. pertussis 18323, and CFU 
counts were performed on individual lung homogenate. 
Results are mean viable B. pertussis counts from five mice per 
group. An asterisk symbol (*) indicates a statistically signifi-
cant difference (P < 0.05) between immunized and control 
group.
Protection against intracerebral challenge with B. pertussisFigure 5
Protection against intracerebral challenge with B. 
pertussis. Three weeks after immunization, all mice (sixteen 
mice per group) were challenged intracerebrally with a lethal 
dose of B. pertussis 18323, and survival of challenge mice was 
monitored. For recombinant proteins immunized groups, A, 
B, and C indicated 100 μg, 20 μg, and 4 μg dose of immuniza-
tion. The reference vaccine is used as national reference 
standard in the intracerebral challenge assay in China and this 
standard have an assigned activity of 14 IU/ampoule. A, B and 
C indicated 0.5 IU, 0.1 IU and 0.02 IU dose of immunization. 
All mice of control group were immunized adjuvant alone. 
An asterisk symbol (*) indicates a significant difference (P < 
0.05) between immunized and control group.Page 4 of 8
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similar feature with the native form of Prn, suggesting that
B cell and T cell epitopes might be highly conserved in
rPrn.
Murine intranasal and intracerebral challenge assays have
been validated and used to demonstrate the protection of
pertussis vaccine for many years [30-32]. The results
obtained from the intranasal and intracerebral challenge
tests strongly suggest that rPrn functions as a protective
antigen. These observations are consistent with previous
reports that a higher Th1-type response was associated
with a stronger level of protection against B. pertussis [29].
In this study, the bacterial loads were only evaluated on
day 7 in lungs of the mince after the intranasal challenge.
However, a time course of infection would probably pro-
vide more information on the protective properties of the
proteins studied.
So far, twelve, two and four different variants have been
reported in Prn, Fim2 and Fim3, respectively [17,18,33].
At present, the prevalent allele combinations of B. pertussis
isolates are prn2/fim3B [18]. The strains used in this study
and the strains used for vaccine production are prn1/fim3A
or prn6/fim3A. As the difference occurred between B. per-
tussis vaccine strains and circulating isolates in many
countries [16-18,33], it has been proposed that the strain
variation may have effect on the vaccine efficacy [16]. In
this case, engineering strategies will remedy antigenic
shifts by performing genetic mutation on the antigen
encoding genes, which is an advantage of using recom-
binant proteins compared with the ones purified from B.
pertussis.
Because of the similarity in the molecular weight, it is
extremely difficult to purify separately Fim2 and Fim3
proteins from B. pertussis. Therefore, antibody responses
against Fim2 or Fim3 were only measured in ELISA using
a mixture of Fim2 and Fim3 proteins as coating antigen in
clinical vaccine trials [8,34]. The exact role of Fim2 and
Fim3 in protection against pertussis is not fully known. In
this study, recombinant Fim2 and Fim3 were expressed
and purified separately. For the first times, their functions
in protection against pertussis were assessed separately in
mice model. The study demonstrated that higher anti-
body titres and cellular immune response characteristic of
increased production of IL-2 were induced in mice immu-
nized with rFim2 and rFim3. Although monoclonal anti-
Fim2 and anti-Fim3 antibodies were used in the study, it
remains to be shown whether there is cross-reacting
response between Fim2 and Fim3.
It is known that IL-2, TNF-α and IFN-γ are characteristic
cytokines for Th1 response, and IL-4 and IL-10 for Th2
response [29]. In this study, we have only measured serum
concentrations of IL-2, TNF-α and IL-4. It is interesting to
study concentrations of other cytokines such as IFN-γ in
sera collected from mice after immunization and infec-
tion. Further, serum IL-4 was not measurable in all mice
tested in this study. This was in contrast to the finding that
IL-2 and TNF-α were significantly induced. The exact rea-
son for the undetectable IL-4 was unknown. One explana-
tion might be the NIH mice used in this study. It is known
that NIH mice predominate on cellular immunity.
Another explanation might be timing of the serum sam-
pling and possible posttranscriptional regulation of IL-4.
No matter if IL-4 was measurable or not, anti-pertussis
antibodies were significantly induced in mice immunized
with each of the three recombinant proteins.
Previous vaccine efficacy trial in Sweden indicated that
inclusion of Prn, Fim2 and Fim3 into acellular vaccine
containing PT and FHA provided higher protection
against pertussis. However, the contribution of individual
components in the protection was not revealed [8]. Since
Fim of B. pertussis facilitates a variety of binding capabili-
ties as adhesins [35], some studies suggested that passive
protection against B. pertussis infection might be conferred
due to the existence of higher titres of anti-Fim2 or anti-
Fim3 antibodies which might transmigrate into the lower
respiratory tract in mice [36,37]. In contrast, the results
from intranasal and intracerebral challenges with B. per-
tussis indicated very limited role played by rFims in bacte-
rial clearance, although higher titres of anti-Fim
antibodies have been observed in this study. These data
suggest that rFim2 or rFim3 alone may not be enough to
provide the protection against B. pertussis and that they
should be used in combination with other vaccine com-
ponents such as PT, FHA, and/or Prn.
Conclusions
B. pertussis proteins Prn, Fim2, and Fim3 can be geneti-
cally manipulated and expressed in a large amount in
vitro. The three recombinant proteins can elicit both
humoral and cellular immune responses. Immunization
with rPrn can confer certain protection in mouse infection
models. These recombinant proteins, especially rPrn, have
a potential for the development of a new generation of
APVs in developing countries such as China.
Methods
Bacterial strains and culture conditions
B. pertussis strain CS (prn/fim2/fim3 allele type: 1/1/A), a
Chinese strain isolated in Beijing and used for production
of pertussis vaccine, has been described previously [9].
Genomic DNA of this strain was used to generate recom-
binant proteins. B. pertussis strain 18323 (prn/fim2/fim3
allele type: 6/1/A), an international reference strain, was
used in the mouse intranasal and intracerebral challenge
assays. B. pertussis strains were grown at 37°C on Bordet-
Gengou (BG) agar (Difco) medium supplemented with
20% defibrinated sheep blood. E. coli strains BL21 (DE3)Page 5 of 8
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used for the protein expressions. They were cultured in
Luria Broth (LB) medium at 37°C.
Recombinant protein expression and purification
Construction of recombinant DNA fragments, protein
expression and purification were performed as described
previously [38]. Briefly, DNAs encoding Prn and Fim3
were amplified by PCR with primers listed in Table 1 from
genomic DNA of B. pertussis strain CS and ligated into
pQE30 vector (Qiagen, Germany) with restriction sites
BamHI and HindIII. The generated plasmids were desig-
nated pQE30/Prn and pQE30/Fim3. By using a similar
approach, DNA encoding Fim2 was amplified by PCR and
ligated into pET30a (+) (Novagen, Germany) with NdeI
and XhoI restriction sites. The plasmid was named as
pET30a (+)/Fim2. The three constructed plasmids were
transformed into E. coli BL21 (DE3) or M15, respectively.
The cloned DNA sequences were verified by DNA
sequencing analysis. The nucleotide sequences of fim2
and fim3 have been submitted to GenBank with accession
numbers AY845256 and AY845257.
Expression of the recombinant proteins was induced by
addition of IPTG to a final concentration of 1 mM.
Expressed proteins were purified using the HisTrap™ HP
column by the AKTA system (Amersham Pharmacia, USA)
according to the manufacturer's recommendations.
Briefly, the cells expressing recombinant proteins were
collected by centrifugation, and the pellets were sonicated
on ice-bath. The inclusion bodies of the recombinant pro-
teins were separated by centrifugation at 12,000 × g for 10
minutes at 4°C and solubilized in a buffer solution (pH =
7.4) containing 10 mM Na2HPO4, 10 mM NaH2PO4, 500
mM NaCl and 8 M urea. Protein renature was processed
by gradually decreasing the concentration of urea to 0.5 M
with dialyzing for 48 hours. The proteins were then puri-
fied by passing through a Ni2+ affinity chromatography. A
binding buffer (10 mM Na2HPO4, 10 mM NaH2PO4, 500
mM NaCl, 20 mM imidazole, 0.5 M urea, pH 7.4) and an
elution buffer (10 mM Na2HPO4, 10 mM NaH2PO4, 500
mM NaCl, 200 mM imidazole, 0.5 M urea, pH 7.4) were
used for the protein binding and elution procedures. The
purity of each recombinant protein was estimated by 10%
SDS-PAGE and densitometry analysis, while the protein
concentration was determined by the Lowry method as
described previously [38].
Western immunoblotting
Western immunoblotting was performed as described by
Towbin et al [39]. In brief, recombinant proteins were sep-
arated by SDS-PAGE and transferred onto nitrocellulose
membranes using a semi-dry western transfer apparatus
(Bio-Rad, USA) at a constant voltage (20 V). Non-specific
binding sites of the membranes were blocked by incuba-
tion with 5% skim milk (Fluka, USA) in phosphate-buff-
ered solution (PBS) (pH 7.4) containing 0.05% Tween 20
for 1 h. The blots were then incubated with the specific
anti-Prn, anti-Fim2 or anti-Fim3 antibodies, kindly pro-
vided by Dr. Dorothy Xing, National Institute for Biologi-
cal Standards and Control, UK. The blot signals were
captured by using a DAB kit (Boster, China) following
incubation with horseradish peroxidase-conjugated anti-
mouse secondary IgG (Jackson, USA).
Immunization of mice
Male and female NIH mice, at 17-20 days old of age, were
obtained from the animal center at the National Institute
for the Control of Pharmaceutical and Biological Products
(Beijing, China). For the immunogenic study and intrana-
sal challenge assays, mice were divided into seven groups
(ten female mice in each group). Each mouse was immu-
nized intraperitoneally on day 0 and 14 with 0.5 mL of
each recombinant protein at two concentrations (20 or 4
μg/mouse), absorbed with adjuvant Al(OH)3 (0.5 mg per
mouse). In control group, ten mice were only immunized
intraperitoneally with Al(OH)3 (0.5 mg per mouse). Two
weeks after the second immunization (day 28), five mice
from each group were challenged intranasally, and serum
samples were collected from the remaining five mice.
For the intracerebral challenge assays, thirteen groups of
mice, consisting eight male and eight female mice in each
group, were used. Each mouse was immunized intraperi-
toneally with 0.5 mL of either different concentrations
(100, 20, or 4 μg/mouse) of each recombinant protein
formulated with adjuvant Al(OH)3 (0.5 mg per mouse),
or with a reference vaccine at different doses (0.5, 0.1, or
0.02 IU/mouse). The reference vaccine is a lyophilized
WPV which is being used as a national standard of the
Table 1: Primers used in the study
Gene Size (bp) Primer Sequences (5'-3')
Prn 2031 Prn-p1 CATAGGATCCGACTGGAACAACCAGTCCATCGTCA
Prn-p2 CAGAAAGCTTGCCGCCGTCGCCGGTGAAGCCG
Fim2 543 Fim2-p3 CATACATATGGACGACGGCACCATCGTCATCACCGGC
Fim2-p4 GTAACTCGAGGGGGTAGACCACGGAAAAACCCACATA
Fim3 546 Fim3-p5 CTATGGATCCGCGCTGGCCAACGACGGCACCATCGTC
Fim3-p6 ACTTAAGCTTGGGGTAGACGACGGAAAAGCCGACGTA
The restriction site is underlinedPage 6 of 8
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in China [40]. The vaccine has an assigned activity of 14
IU/ampoule. Sixteen NIH mice (female and male in half)
that were only immunized intraperitoneally with
Al(OH)3 alone were used as a control group.
The experiments were supervised by the Animal Ethic
Committee of National Institute for the Control of Phar-
maceutical and Biological Products, Beijing.
Antibody measurement
Mouse serum antibodies against rPrn, rFim2 and rFim3
were measured by enzyme-linked immunosorbent assays
(ELISA). Microtiter plates (Greiner, Germany) were
coated with 50 μL of 0.05 M carbonate buffer (pH 9.6)
containing 5 μg/mL of the purified recombinant protein.
After blocking with PBS containing 0.05% Tween 20 and
1% bovine serum albumin, 50 μL of anti-serum was
added in two-fold serial dilutions. Following incubation
for 1 h at 37°C, goat anti-mouse IgG conjugated with
horseradish peroxidase (Pierce, USA) were added to the
plates. After another incubation at the same condition,
signals were measured by using 2, 2'-azinobis (3-ethyl-
benzthiazolinesulfonic acid) (ABTS, Boehringer Man-
nheim, Germany) substrate according to the
manufacturer's instruction. Results were expressed as the
highest dilution yielding the absorbance at 405 nm three
times above the control values.
Cytokine measurement
Cytokine concentrations of IL-2, IL-4 and TNF-α in sera of
the mice immunized with 20 μg dose of recombinant
antigens were determined using a sandwich ELISA kit
(Boster, China) according to the manufacturer's instruc-
tion. The detection limit of these three cytokines was 2.4
pg/ml for IL-2, 3.1 pg/ml for IL-4 and 1.6 pg/ml for TNF-
α, respectively.
Intranasal challenge with B. pertussis
Two week after the second immunization, five mice from
each group were challenged intranasally with the B. pertus-
sis strain 18323 according to the method described by
Cheung et al [30]. Bacteria were subcultured on BG agar
medium containing 20% defibrinated sheep blood and
resuspended in PBS with 1% casamino acids. For each
anesthetized mouse, 50 μL of bacterial suspension at
approximately 1 × 106 CFU was injected into the nostril.
On day 7 after the injection, lungs of each mouse were
removed and homogenized in 1 mL of PBS. Bacterial via-
ble counting was performed by plating serial dilutions on
BG agar medium.
Intracerebral challenge with B. pertussis
The B. pertussis strain 18323 was used for the intracerebral
challenge assay for the immunized mice. Bacterial suspen-
sion (30 μL) with approximately 8 × 104 CFU suspended
in PBS containing 1% casamino acids were injected into
the mouse brain using a 0.25-mL glass syringe. Animal
survival number was enumerated at 14 days post chal-
lenge.
Statistical analysis
All analyses were performed by use of SPSS 13.0 software.
One-way analysis of variance followed by Dunnett's (two-
sided) test was utilized for the statistical analysis of the
host immune responses and protection against intranasal
challenges with B. pertussis in mice. To compare the differ-
ence for the protective efficacies against intracerebral chal-
lenge with a lethal dose of B. pertussis, the data were
analyzed by a Chi-Square test (Mantel-Haenszed
Method). P-value < 0.05 was considered statistically sig-
nificant.
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